Penn Center for Myeloproliferative Neoplasms

Edward A. Stadtmauer

faculty photo

Edward A. Stadtmauer

Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-7910
Fax: 215-615-5888
Education:
A.B. (Biochemistry)
Cornell University, College of Arts and Sciences, 1979.
M.D. (Medicine)
University of Pennsylvania School of Medicine, 1983.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical trials, Bone Marrow Transplant

Description of Clinical Expertise

Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant

Selected Publications

D'Souza Anita, Pasquini Marcelo, Logan Brent, Giralt Sergio, Krishnan Amrita, Antin Joseph, Howard Alan, Goodman Stacy, Qazilbash Muzzafar, Knust Kristin, Sahebi Firoozeh, Weisdorf Daniel, Vesole David, Stadtmauer Edward, Maloney David, Hari Parameswaran: Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. British journal of haematology 178(5): 816-819, Sep 2017.

Bair Steven M, Strelec Lauren, Nagle Sarah J, Nasta Sunita D, Landsburg Daniel J, Mato Anthony R, Loren Alison W, Schuster Stephen J, Stadtmauer Edward A, Svoboda Jakub: Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. American journal of hematology 92(9): 879-884, Sep 2017.

Holstein Sarah A, Jung Sin-Ho, Richardson Paul G, Hofmeister Craig C, Hurd David D, Hassoun Hani, Giralt Sergio, Stadtmauer Edward A, Weisdorf Daniel J, Vij Ravi, Moreb Jan S, Callander Natalie S, van Besien Koen, Gentile Teresa G, Isola Luis, Maziarz Richard T, Bashey Asad, Landau Heather, Martin Thomas, Qazilbash Muzaffar H, Rodriguez Cesar, McClune Brian, Schlossman Robert L, Smith Scott E, Hars Vera, Owzar Kouros, Jiang Chen, Boyd Molly, Schultz Chelsea, Wilson Marcia, Hari Parameswaran, Pasquini Marcelo C, Horowitz Mary M, Shea Thomas C, Devine Steven M, Linker Charles, Anderson Kenneth C, McCarthy Philip L: Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. The Lancet. Haematology 4(9): e431-e442, Sep 2017.

Scott Emma C, Maziarz Richard T, Spurgeon Stephen E, Medvedova Eva, Gajewski James, Reasor-Heard Shara, Park Byung, Kratz Anne, Thomas George V, Loriaux Marc, Cascio Michael, Podolak Jennifer, Gordon Miranda, Botelho Jennifer, Stadtmauer Edward, Amaravadi Ravi, Vogl Dan T: Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica 102(7): e261-e265, Jul 2017.

Cheng Yee Chung, Shi Yushu, Zhang Mei-Jie, Brazauskas Ruta, Hemmer Michael T, Bishop Michael R, Nieto Yago, Stadtmauer Edward, Ayash Lois, Gale Robert Peter, Lazarus Hillard, Holmberg Leona, Lill Michael, Olsson Richard F, Wirk Baldeep Mona, Arora Mukta, Hari Parameswaran, Ueno Naoto: Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer 8(6): 1009-1017, 2017.

Narayan Vivek, Gunnarsson Orvar, Hwang Wei-Ting, Squillante Christian M, Nathanson Katherine L, Stadtmauer Edward A, Vaughn David J: Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. Clinical genitourinary cancer 14(6): 524-529, Dec 2016.

Yam Clinton, Crisalli Lisa, Luger Selina M, Loren Alison W, Hexner Elizabeth O, Frey Noelle V, Mangan James K, Gao Amy, Stadtmauer Edward A, Porter David L, Reshef Ran: Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American journal of hematology 91(9): 883-7, Sep 2016.

Yam Clinton, Landsburg Daniel J, Nead Kevin T, Lin Xinyi, Mato Anthony R, Svoboda Jakub, Loren Alison W, Frey Noelle V, Stadtmauer Edward A, Porter David L, Schuster Stephen J, Nasta Sunita D: Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. American journal of hematology 91(7): 672-6, Jul 2016.

Jacobus S J, Rajkumar S V, Weiss M, Stewart A K, Stadtmauer E A, Callander N S, Dreosti L M, Lacy M Q, Fonseca R: Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood cancer journal 6(7): e448, Jul 2016.

Kumar Anita J, Vassilev Pavel, Loren Alison W, Luger Selina M, Reshef Ran, Gill Saar, Smith Jacqueline, Goldstein Steven C, Hexner Elizabeth, Stadtmauer Edward A, Porter David, Frey Noelle V: Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. American journal of hematology 91(4): 426-9, Jun 2016.

back to top
Last updated: 10/19/2017
The Trustees of the University of Pennsylvania
 

The Penn Difference

  • Individualized Treatment Plan
  • Expert Treatment Team Knowledgeable in Myeloproliferative Disorders
  • State-of-the-Art Personalized Diagnostic Testing
  • Access to Newest Therapies Through Clinical Trials
  • Comprehensive Bone Marrow Transplantation Service
  • Integrated Care by a Multidisciplinary Treatment Team

Make an Appointment

New Patients:
Abramson Cancer Center
Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
Philadelphia, PA 19104
Phone: 215-615-5858 option 2
Fax: 215-615-5889

Current Patients:
Contact your doctor directly

For General Inquiries:
Call the Myeloproliferative Neoplasms Program at  215-614-1847


Donate


Search